Hostname: page-component-cd9895bd7-fscjk Total loading time: 0 Render date: 2024-12-23T18:14:43.959Z Has data issue: false hasContentIssue false
  • English
  • Français

Patterns of Depo-Provera use in a large family planning clinic in the United States

Published online by Cambridge University Press:  31 July 2008

James E. Higgins ,
I-Cheng Chi ,
Lynne R. Wilkens  and
Robert A. Hatcher
James E. Higgins
Affiliation:
Family Health International, Research Triangle Park, NC
I-Cheng Chi
Affiliation:
Family Health International, Research Triangle Park, NC
Lynne R. Wilkens
Affiliation:
Family Health International, Research Triangle Park, NC
Robert A. Hatcher
Affiliation:
Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, Georgia, USA
Get access Rights & Permissions [Opens in a new window]

Summary

Depot medroxyprogesterone acetate (DMPA) was approved as an investigational new drug for contraceptive use in the United States between 1967 and 1978. Patterns of contraceptive choice and changing methods were determined among 36,298 women attending a family planning clinic between 1967 and 1976. This population was the largest concentration of US women who had DMPA available as a contraceptive option. By 1974, women in the age group 35–49 were as likely to choose DMPA as either oral contraception or an intrauterine device. Coincidentally, use of the most popular choice, oral contraception, declined in older women and IUD use dropped sharply in all age groups. On average, users of DMPA were more likely to continue their method than were users of IUDs or barrier methods. Among women in the 35–49 age group, DMPA users were the group least likely to change methods.

Type
Research Article
Information
Journal of Biosocial Science , Volume 18 , Issue 4 , October 1986 , pp. 379 - 386
Copyright
Copyright © Cambridge University Press 1986

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Editorial (1985) Depo-Provera marketed for long-term use. Pharmaceut. J. 234, 173.Google Scholar
Higgins, J.E., Wilkens, L.R., Chi, I-C. & Hatcher, R.A. (1985) Hospitalizations among black women using contraceptives. Am. J. Obstet. Gynec. 153, 280.Google Scholar
Population Information Program (1983) Long-acting Progestins—Promise and Prospects. Population Reports, Series K, No. 2 Johns Hopkins University, Baltimore, Maryland.Google Scholar
Swenson, I., Khan, A.R. & Jahan, F.A. (1980) A randomized single blind comparative trial of norethindrone enanthate and depo-medroxyprogesterone acetate in Bangladesh. Contraception, 21, 207.Google Scholar
World Health Organization (1981) Special Programme of Research, Development and Research Training in Human Reproduction: Tenth Annual Report, WHO, Geneva.Google Scholar
World Health Organization (1978) Multinational comparative clinical evaluation of two long-acting injectable contraceptive steroids; norethisterone oenanthate and medroxyprogesterone acetate: bleeding patterns and side effects. Contraception, 17, 395.Google Scholar